Abstract
BackgroundNowadays, rheumatoid arthritis (RA) patients can benefit from several drugs classified as biologic (b) or JAK inhibitors (JAKi). Four JAKi are now available, whose two JAKi, with predominantly JAK1 selectivity...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have